Reduced plasma orexin-A levels in patients with bipolar disorder

References

• Scammell TE, Winrow CJ. Orexin receptors: pharmacology and therapeutic opportunities. Annu Rev Pharmacol Toxicol. 2011;51:243–266. doi:10.1146/annurev-pharmtox-010510-10052821034217
   PubMed Web of Science ®Google Scholar
• Marcus JN, Aschkenasi CJ, Lee CE, et al. Differential expression of orexin receptors 1 and 2 in the rat brain. J Comp Neurol. 2001;435:6–25.11370008
   PubMed Web of Science ®Google Scholar
• Blanco M, López M, GarcIa-Caballero T, et al. Cellular localization of orexin receptors in human pituitary. J Clin Endocrinol Metab. 2001;86:1616–1619. doi:10.1210/jcem.86.7.7433
   Google Scholar
• Mazzocchi G, Malendowicz LK, Gottardo L, Aragona F, Nussdorfer GG. Orexin A stimulates cortisol secretion from human adrenocortical cells through activation of the adenylate cyclase-dependent signaling cascade. J Clin Endocrinol Metab. 2001;86:778–782. doi:10.1210/jcem.86.2.723311158046
   PubMed Web of Science ®Google Scholar
• Nishino S. The hypocretin/orexin receptor: therapeutic prospective in sleep disorders. Expert Opin Investig Drugs. 2007;16:1785–1797. doi:10.1517/13543784.16.11.1785
   PubMed Web of Science ®Google Scholar
• Sakurai T, Amemiya A, Ishii M, et al. Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. Cell. 1998;92:573–585.9491897
   PubMed Web of Science ®Google Scholar
• Nambu T, Sakurai T, Mizukami K, Hosoya Y, Yanagisawa M, Goto K. Distribution of orexin neurons in the adult rat brain. Brain Res. 1999;827:243–260.10320718
   PubMed Web of Science ®Google Scholar
• Peyron C, Tighe DK, van Den Pol AN, et al. Neurons containing hypocretin (orexin) project to multiple neuronal systems. J Neurosci. 1998;18:9996–10015.9822755
   PubMed Web of Science ®Google Scholar
• Ripley B, Overeem S, Fujiki N, et al. CSF hypocretin/orexin levels in narcolepsy and other neurological conditions. Neurology. 2001;57:2253–2258. doi:10.1212/wnl.57.12.225311756606
   PubMed Web of Science ®Google Scholar
• Mignot E, Lammers GJ, Ripley B, et al. The role of cerebrospinal fluid hypocretin measurement in the diagnosis of narcolepsy and other hypersomnias. Arch Neurol. 2002;59:1553–1562.12374492
   PubMed Web of Science ®Google Scholar
• Saper CB, Scammell TE, Lu J. Hypothalamic regulation of sleep and circadian rhythms. Nature. 2005;437:1257–1263. Review. doi:10.1038/nature0428416251950
   PubMed Web of Science ®Google Scholar
• Yamuy J, Fung SJ, Xi M, Chase MH. Hypocretinergic control of spinal cord motoneurons. J Neurosci. 2004;24:5336–5345. doi:10.1523/JNEUROSCI.4812-03.200415190106
   PubMed Web of Science ®Google Scholar
• Plazzi G, Moghadam KK, Maggi LS, et al. Autonomic disturbances in narcolepsy. Sleep Med Rev. 2011;15:187–196. doi:10.1016/j.smrv.2010.05.00220634114
   PubMed Web of Science ®Google Scholar
• Tsujino N, Sakurai T. Role of orexin in modulating arousal, feeding, and motivation. Front Behav Neurosci. 2013;7:28. doi:10.3389/fnbeh.2013.0002823616752
   PubMed Web of Science ®Google Scholar
• Singareddy R, Uhde T, Commissaris R. Differential effects of hypocretins on noise-alone versus potentiated startle responses. Physiol Behav. 2006;89:650–655. doi:10.1016/j.physbeh.2006.08.00417028045
   PubMed Web of Science ®Google Scholar
• Korotkova TM, Brown RE, Sergeeva OA, Ponomarenko AA, Haas HL. Effects of arousal- and feeding-related neuropeptides on dopaminergic and GABAergic neurons in the ventral tegmental area of the rat. Eur J Neurosci. 2006;23:2677–2685. doi:10.1111/j.1460-9568.2006.04792.x16817870
   PubMed Web of Science ®Google Scholar
• Bubser M, Fadel JR, Jackson LL, Meador-Woodruff JH, Jing D, Deutch AY. Dopaminergic regulation of orexin neurons. Eur J Neurosci. 2005;21:2993–3001. doi:10.1111/j.1460-9568.2005.04121.x15978010
   PubMed Web of Science ®Google Scholar
• Sarchielli P, Rainero I, Coppola F, et al. Involvement of corticotrophin-releasing factor and orexin-A in chronic migraine and medication-overuse headache: findings from cerebrospinal fluid. Cephalalgia. 2008;28:714–722. doi:10.1111/j.1468-2982.2008.01566.x18479471
   PubMed Web of Science ®Google Scholar
• Cowen P. Neuroendocrine and neurochemical processes in depression. Psychopathol Rev. 2015;3:3–15.
   Google Scholar
• Lieberman JA, Koreen AR. Neurochemistry and neuroendocrinology of schizophrenia: a selective review. Schizophr Bull. 1993;19:371–429. Review. doi:10.1093/schbul/19.2.3718100644
   PubMed Web of Science ®Google Scholar
• Kunugi H, Hori H, Ogawa S. Biochemical markers subtyping major depressive disorder. Psychiatry Clin Neurosci. 2015;69:597–608. doi:10.1111/pcn.1229925825158
   PubMed Web of Science ®Google Scholar
• Johnson PL, Truitt W, Fitz SD, et al. A key role for orexin in panic anxiety. Nat Med. 2010;16:111–115. doi:10.1038/nm.207520037593
   PubMed Web of Science ®Google Scholar
• Plaza-Zabala A, Martín-García E, de Lecea L, Maldonado R, Berrendero F. Hypocretins regulate the anxiogenic-like effects of nicotine and induce reinstatement of nicotine-seeking behavior. J Neurosci. 2010;30:2300–2310. doi:10.1523/JNEUROSCI.5724-09.201020147556
   PubMed Web of Science ®Google Scholar
• Heydendael W, Sharma K, Iyer V, et al. Orexins/hypocretins act in the posterior paraventricular thalamic nucleus during repeated stress to regulate facilitation to novel stress. Endocrinology. 2011;152:4738–4752. doi:10.1210/en.2011-165221971160
   PubMed Web of Science ®Google Scholar
• Staples LG, Cornish JL. The orexin-1 receptor antagonist SB-334867 attenuates anxiety in rats exposed to cat odor but not the elevated plus maze: an investigation of trial 1 and trial 2 effects. Horm Behav. 2014;65:294–300. doi:10.1016/j.yhbeh.2013.12.01424397997
   PubMed Web of Science ®Google Scholar
• Ito N, Yabe T, Gamo Y, et al. I.c.v. administration of orexin-A induces an antidepressive-like effect through hippocampal cell proliferation. Neuroscience. 2008;157:720–732. doi:10.1016/j.neuroscience.2008.09.04218952152
   PubMed Web of Science ®Google Scholar
• Allard JS, Tizabi Y, Shaffery JP, Trouth CO, Manaye K. Stereological analysis of the hypothalamic hypocretin/orexin neurons in an animal model of depression. Neuropeptides. 2004;38:311–315. doi:10.1016/j.npep.2004.06.00415464197
   PubMed Web of Science ®Google Scholar
• Lutter M, Krishnan V, Russo SJ, Jung S, McClung CA, Nestler EJ. Orexin signaling mediates the antidepressant-like effect of calorie restriction. J Neurosci. 2008;28:3071–3075. doi:10.1523/JNEUROSCI.5584-07.200818354010
   PubMed Web of Science ®Google Scholar
• Nocjar C, Zhang J, Feng P, Panksepp J. The social defeat animal model of depression shows diminished levels of orexin in mesocortical regions of the dopamine system, and of dynorphin and orexin in the hypothalamus. Neuroscience. 2012;218:138–153. doi:10.1016/j.neuroscience.2012.05.03322626650
   PubMed Web of Science ®Google Scholar
• Rasmussen K, Hsu MA, Noone S, Johnson BG, Thompson LK, Hemrick-Luecke SK. The orexin-1 antagonist SB-334867 blocks antipsychotic treatment emergent catalepsy: implications for the treatment of extrapyramidal symptoms. Schizophr Bull. 2007;33:1291–1297. doi:10.1093/schbul/sbm08717660489
   PubMed Web of Science ®Google Scholar
• Rasmussen K, Hsu MA, Yang Y. The orexin-1 receptor antagonist SB-334867 blocks the effects of antipsychotics on the activity of A9 and A10 dopamine neurons: implications for antipsychotic therapy. Neuropsychopharmacology. 2007;32:786–792. doi:10.1038/sj.npp.130123917063151
   PubMed Web of Science ®Google Scholar
• Brundin L, Björkqvist M, Petersén A, Träskman-Bendz L. Reduced orexin levels in the cerebrospinal fluid of suicidal patients with major depressive disorder. Eur Neuropsychopharmacol. 2007;17:573–579. doi:10.1016/j.euroneuro.2007.01.00517346943
   PubMed Web of Science ®Google Scholar
• Brundin L, Petersén A, Björkqvist M, Träskman-Bendz L. Orexin and psychiatric symptoms in suicide attempters. J Affect Disord. 2007;100:259–263. doi:10.1016/j.jad.2006.10.01917141878
   PubMed Web of Science ®Google Scholar
• Brundin L, Björkqvist M, Träskman-Bendz L, Petersén A. Increased orexin levels in the cerebrospinal fluid the first year after a suicide attempt. J Affect Disord. 2009;113:179–182. doi:10.1016/j.jad.2008.04.01118533274
   PubMed Web of Science ®Google Scholar
• Rotter A, Asemann R, Decker A, Kornhuber J, Biermann T. Orexin expression and promoter-methylation in peripheral blood of patients suffering from major depressive disorder. J Affect Disord. 2011;131:186–192. doi:10.1016/j.jad.2010.12.00421211849
   PubMed Web of Science ®Google Scholar
• Salomon RM, Ripley B, Kennedy JS, et al. Diurnal variation of cerebrospinal fluid hypocretin-1 (Orexin-A) levels in control and depressed subjects. Biol Psychiatry. 2003;54:96–104.12873798
   PubMed Web of Science ®Google Scholar
• Schmidt FM, Brügel M, Kratzsch J, et al. Cerebrospinal fluid hypocretin-1 (orexin A) levels in mania compared to unipolar depression and healthy controls. Neurosci Lett. 2010;483:20–22. doi:10.1016/j.neulet.2010.07.03820655364
   PubMed Web of Science ®Google Scholar
• Schmidt FM, Arendt E, Steinmetzer A, et al. CSF-hypocretin-1 levels in patients with major depressive disorder compared to healthy controls. Psychiatry Res. 2011;190:240–243. doi:10.1016/j.psychres.2011.06.00421757240
   PubMed Web of Science ®Google Scholar
• Nishino S, Ripley B, Mignot E, Benson KL, Zarcone VP. CSF hypocretin-1 levels in schizophrenics and controls: relationship to sleep architecture. Psychiatry Res. 2002;110:1–7.12007588
   PubMed Web of Science ®Google Scholar
• Dalal MA, Schuld A, Pollmächer T. Lower CSF orexin A (hypocretin-1) levels in patients with schizophrenia treated with haloperidol compared to unmedicated subjects. Mol Psychiatry. 2003;8:836–837. doi:10.1038/sj.mp.400136314515133
   PubMed Web of Science ®Google Scholar
• Kastin AJ, Akerstrom V. Orexin A but not orexin B rapidly enters brain from blood by simple diffusion. J Pharmacol Exp Ther. 1999;289:219–223.10087007
   PubMed Web of Science ®Google Scholar
• Strawn JR, Pyne-Geithman GJ, Ekhator NN, et al. Low cerebrospinal fluid and plasma orexin-A (hypocretin-1) concentrations in combat-related posttraumatic stress disorder. Psychoneuroendocrinology. 2010;35:1001–1007. doi:10.1016/j.psyneuen.2010.01.00120116928
   PubMed Web of Science ®Google Scholar
• Chien YL, Liu CM, Shan JC, et al. Elevated plasma orexin A levels in a subgroup of patients with schizophrenia associated with fewer negative and disorganized symptoms. Psychoneuroendocrinology. 2015;53:1–9. doi:10.1016/j.psyneuen.2014.12.01225560205
   PubMed Web of Science ®Google Scholar
• Nishino S, Mignot E. Article reviewed: plasma orexin-A is lower in patients with narcolepsy. Sleep Med. 2002;3(4):377–378.14592205
   PubMedGoogle Scholar
• Higuchi S, Usui A, Murasaki M, et al. Plasma orexin-A is lower in patients with narcolepsy. Neurosci Lett. 2002;318:61–64.11796186
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th (DSM-IV) Washington, DC: American Psychiatric Association; 1994.
   Google Scholar
• Sheehan DV, Lecrubier Y, Sheehan KH, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1998;59(Suppl 20):22–33.
   PubMed Web of Science ®Google Scholar
• Otsubo T, Tanaka K, Koda R, et al. Reliability and validity of Japanese version of the Mini-International Neuropsychiatric Interview. Psychiatry Clin Neurosci. 2005;59:517–526. doi:10.1111/j.1440-1819.2005.01408.x16194252
   PubMed Web of Science ®Google Scholar
• World Medical Assocition. World Medical Association Declaration of Helsinki: ethical principles for medical reseach involving humansubjects. Jama. 2000;284:3043–3045.11122593
   PubMed Web of Science ®Google Scholar
• Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13:261–276. doi:10.1093/schbul/13.2.2613616518
   PubMed Web of Science ®Google Scholar
• Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;56–62. doi:10.1136/jnnp.23.1.5614399272
   PubMed Web of Science ®Google Scholar
• Zimmerman M, Martinez JH, Young D, Chelminski I, Dalrymple K. Severity classification on the Hamilton depression rating scale. J Affect Disord. 2013;150:384–388. doi:10.1016/j.jad.2013.04.02823759278
   PubMed Web of Science ®Google Scholar
• Inada T, Inagaki A. Psychotropic dose equivalence in Japan. Psychiatry Clin Neurosci. 2015;69:440–447. doi:10.1111/pcn.1227525601291
   PubMed Web of Science ®Google Scholar
• Kaskie RE, Graziano B, Ferrarelli F. Schizophrenia and sleep disorders: links, risks, and management challenges. Nat Sci Sleep. 2017;9:227–239. doi:10.2147/NSS.S12107629033618
   PubMed Web of Science ®Google Scholar
• Abreu T, Bragança M. The bipolarity of light and dark: a review on bipolar disorder and circadian cycles. J Affect Disord. 2015;185:219–229. doi:10.1016/j.jad.2015.07.01726241867
   PubMed Web of Science ®Google Scholar
• Germain A, Kupfer DJ. Circadian rhythm disturbances in depression. Hum Psychopharmacol. 2008;23:571–585. doi:10.1002/hup.96418680211
   PubMed Web of Science ®Google Scholar
• Harvey AG. Sleep and circadian rhythms in bipolar disorder: seeking synchrony, harmony, and regulation. Am J Psychiatry. 2008;165:820–829. doi:10.1176/appi.ajp.2008.0801009818519522
   PubMed Web of Science ®Google Scholar
• Takaesu Y, Inoue Y, Ono K, et al. Circadian rhythm sleep-wake disorders as predictors for bipolar disorder in patients with remitted mood disorders. J Affect Disord. 2017;220:57–61. doi:10.1016/j.jad.2017.05.04128595099
   PubMed Web of Science ®Google Scholar
• Robillard R, Naismith SL, Rogers NL, et al. Delayed sleep phase in young people with unipolar or bipolar affective disorders. J Affect Disord. 2013;145:260–263. doi:10.1016/j.jad.2012.06.00622877966
   PubMed Web of Science ®Google Scholar
• Hori H, Koga N, Hidese S, et al. 24-h activity rhythm and sleep in depressed outpatients. J Psychiatr Res. 2016;77:27–34. doi:10.1016/j.jpsychires.2016.02.02226978182
   PubMed Web of Science ®Google Scholar
• Rainero I, Ostacoli L, Rubino E, et al. Association between major mood disorders and the hypocretin receptor 1 gene. J Affect Disord. 2011;130:487–491. doi:10.1016/j.jad.2010.10.03321071097
   PubMed Web of Science ®Google Scholar
• Mäkelä KA, Karhu T, Jurado Acosta A, Vakkuri O, Leppäluoto J, Herzig KH. Plasma orexin-A levels do not undergo circadian rhythm in young healthy male subjects. Front Endocrinol (Lausanne). 2018;9:710. doi:10.3389/fendo.2018.0042030568633
   PubMed Web of Science ®Google Scholar